Product Revenue Reserves and Allowances - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				12 Months Ended
	May 31, 2023	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								$ 46,018	$ 41,404
Upfront cash payment	$ 75,000
Alimera Sciences, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Product rights agreement, closing date								May 17, 2023
Receipt of upfront license fee								$ 75,000
Forecast [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Upfront cash payment							$ 7,500
Product Sales License and Collaboration Revenue or Royalty Income [Member] | Exclusive License Agreement With Betta Pharmaceuticals Company Limited [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								0	0
Royalty Income [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								989	1,137
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								0	300
RPA [Member] | SWK [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								1,000	900
Upfront cash payment								16,500
Deferred revenue, current								1,400	1,200
Deferred revenue, non-current								12,400	13,600
YUTIQ [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								14,232	28,329
DEXYCU [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								$ 0	11,576
Commercial Supply Agreement [Member] | Alimera Sciences, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Initial term of the supply agreement								2 years
Initial Term of Estimated Supply Units								2 years
License and Collaboration Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								$ 30,797	362
License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								100	200
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Intangible assets, net								0
Upfront cash payment								75,000
Deferred revenue, current								37,200
Deferred revenue, non-current								$ 8,300
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period								2028
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Minimum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period								2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								$ 500
Product Rights Agreement [Member] | Forecast [Member] | Alimera Sciences, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Guaranteed payments		$ 1,875	$ 1,875	$ 1,875	$ 1,875		$ 7,500
Product Rights Agreement [Member] | Forecast [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalty payments						$ 70,000
Product [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								14,232	39,905
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								2,100
Product [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								500	$ 400
Transition Services Agreement [Member] | Alimera Sciences, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue								$ 1,000